© 1999 by Oxford University Press
Journal of the National Cancer Institute, Vol. 91, No. 1, 80-85,
January 6, 1999
© 1999 Oxford University Press
REPORTS |
Dormancy of Mammary Carcinoma After Mastectomy
Affiliations of authors: T. G. Karrison, D. J. Ferguson,Departments of Health Studies and Surgery, University of Chicago, IL; P. Meier, Columbia University, New York, NY.
Correspondence to: Theodore G. Karrison, Ph.D., Department of Health Studies, MC2007, University of Chicago, 5841 S. Maryland Ave., Chicago, IL 60637.
BACKGROUND: The longest interval between primary treatment of breast cancer and tumor recurrence, i.e., the limit of breast cancer dormancy, defines the appropriate length of follow-up, the effectiveness of treatment, and curability (no excess mortality risk for patients relative to the general population) for the disease. To determine this limit, we analyzed long-term follow-up data from patients who underwent a radical mastectomy during a four-decade period at the University of Chicago Hospitals. METHODS: For 1547 patients operated on during the period from 1945 through mid-1987, the number of recurrences and deaths occurring within each postoperative year were tabulated, and the hazard rate for first recurrence or death from breast cancer was estimated by use of the actuarial method. The excess mortality rate was calculated for successive 5-year intervals, beginning at the time of mastectomy, by use of U.S. life tables and matching on the basis of age, race, and sex. RESULTS: Most recurrences occurred within the first 10 years after mastectomy. Recurrences were rare after 20 years; only one recurrence was reported among 192 patients followed for 26-45 years. Patients who had a recurrence within 5 years following mastectomy had shorter subsequent survival times than those whose recurrence appeared after 5 years (two-sided P = .0001). The excess death rate increased with pathologic stage of the primary tumor. Overall, there was evidence of excess mortality up to 20 years postsurgery (two-sided P = .009). CONCLUSIONS: The limit of breast cancer dormancy in this patient population appears to be between 20 and 25 years. After this time, recurrences were rare, and the mortality rate was no longer statistically significantly different from that of the general population. Patients surviving to this time without evidence of recurrence or contralateral breast cancer are probably cured.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Y.-C. Chen, D. M. Sosnoski, U. H. Gandhi, L. J. Novinger, K. S. Prabhu, and A. M. Mastro Selenium modifies the osteoblast inflammatory stress response to bone metastatic breast cancer Carcinogenesis, November 1, 2009; 30(11): 1941 - 1948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Demicheli, M. W. Retsky, W. J. M. Hrushesky, M. Baum, and I. D. Gukas The effects of surgery on tumor growth: a century of investigations Ann. Onc., November 1, 2008; 19(11): 1821 - 1828. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. W. L. Teng, J. B. Swann, C. M. Koebel, R. D. Schreiber, and M. J. Smyth Immune-mediated dormancy: an equilibrium with cancer J. Leukoc. Biol., October 1, 2008; 84(4): 988 - 993. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Espana, B. Martin, R. Aragues, C. Chiva, B. Oliva, D. Andreu, and A. Sierra Bcl-xL-Mediated Changes in Metabolic Pathways of Breast Cancer Cells: From Survival in the Blood Stream to Organ-Specific Metastasis Am. J. Pathol., October 1, 2005; 167(4): 1125 - 1137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Meng, D. Tripathy, E. P. Frenkel, S. Shete, E. Z. Naftalis, J. F. Huth, P. D. Beitsch, M. Leitch, S. Hoover, D. Euhus, et al. Circulating Tumor Cells in Patients with Breast Cancer Dormancy Clin. Cancer Res., December 15, 2004; 10(24): 8152 - 8162. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Formenti, M. Volm, K. A. Skinner, D. Spicer, D. Cohen, E. Perez, A. C. Bettini, S. Groshen, C. Gee, B. Florentine, et al. Preoperative Twice-Weekly Paclitaxel With Concurrent Radiation Therapy Followed by Surgery and Postoperative Doxorubicin-Based Chemotherapy in Locally Advanced Breast Cancer: A Phase I/II Trial J. Clin. Oncol., March 1, 2003; 21(5): 864 - 870. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E.-F. Solomayer, M. Feuerer, L. Bai, V. Umansky, P. Beckhove, G. C. Meyberg, G. Bastert, V. Schirrmacher, and I. J. Diel Influence of Adjuvant Hormone Therapy and Chemotherapy on the Immune System Analysed in the Bone Marrow of Patients with Breast Cancer Clin. Cancer Res., January 1, 2003; 9(1): 174 - 180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. N. Naumov, I. C. MacDonald, P. M. Weinmeister, N. Kerkvliet, K. V. Nadkarni, S. M. Wilson, V. L. Morris, A. C. Groom, and A. F. Chambers Persistence of Solitary Mammary Carcinoma Cells in a Secondary Site: A Possible Contributor to Dormancy Cancer Res., April 1, 2002; 62(7): 2162 - 2168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E.-F. Solomayer, I. J. Diel, G. Salanti, M. Hahn, C. Gollan, F. Schutz, and G. Bastert Time Independence of the Prognostic Impact of Tumor Cell Detection in the Bone Marrow of Primary Breast Cancer Patients Clin. Cancer Res., December 1, 2001; 7(12): 4102 - 4108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Klauber-DeMore, K. J. Van Zee, I. Linkov, P. I. Borgen, and W. L. Gerald Biological Behavior of Human Breast Cancer Micrometastases Clin. Cancer Res., August 1, 2001; 7(8): 2434 - 2439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Spratt Re: Dormancy of Mammary Carcinoma After Mastectomy J Natl Cancer Inst, July 5, 2000; 92(13): 1101 - 1101. [Full Text] [PDF]
|
|
|
|
|
|
R. Demicheli, R. Miceli, P. Valagussa, and G. Bonadonna Re: Dormancy of Mammary Carcinoma After Mastectomy J Natl Cancer Inst, February 16, 2000; 92(4): 347 - 348. [Full Text] [PDF]
|
|
|
|
|
|
R. Heimann, F. Lan, R. McBride, and S. Hellman Separating Favorable from Unfavorable Prognostic Markers in Breast Cancer: The Role of E-Cadherin Cancer Res., January 1, 2000; 60(2): 298 - 304. [Abstract] [Full Text]
|
|
|
|
|
|
R. T. Chlebowski, D. E. Collyar, M. R. Somerfield, and D. G. Pfister American Society of Clinical Oncology Technology Assessment on Breast Cancer Risk Reduction Strategies: Tamoxifen and Raloxifene J. Clin. Oncol., June 1, 1999; 17(6): 1939 - 1939. [Abstract] [Full Text] [PDF]
|
|